Benjamin Besse

Benjamin Besse is a leading European thoracic oncologist at Institut Gustave Roussy who has made major contributions to the clinical development of lurbinectedin in SCLC and other novel agents in thoracic malignancies. He led pivotal basket and histotype-specific studies evaluating lurbinectedin's activity, culminating in accelerated FDA approval for platinum-refractory SCLC. His research spans SCLC, NSCLC, and mesothelioma, with a focus on new drug development, biomarker-driven patient selection, and European multicenter clinical trials.